MeiraGTx Holdings plc Ordinary Shares
$12.76
$0.00 (+0.00%)
$12.63Day Range$12.95
Key Statistics
Market Cap
$1.23B
Shares Outstanding
96.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 8, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$12.79
Day High
$12.95
Day Low
$12.63
Volume
917.4K
VWAP
$12.82
Prev Close
$12.76
Transactions
--
Acc. Volume
--
About MeiraGTx Holdings plc Ordinary Shares
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836393 employees655 THIRD AVENUE, NEW YORK, NY, 10017646-860-7985IPO Jun 8, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001735438
- Ticker Root
- MGTX
- SIC Code
- 2836
About MeiraGTx Holdings plc Ordinary Shares (MGTX) Stock
MeiraGTx Holdings plc Ordinary Shares (MGTX) closed the 2026-09-16 session at $12.76, up 0.00% versus the previous close (+0.00). The stock opened at $12.79 and traded between $12.63 and $12.95 during that session. Session trading volume was 917K shares. The volume-weighted average price (VWAP) is $12.82.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
MeiraGTx Holdings plc Ordinary Shares has a market capitalization of $1.23 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. MGTX is listed on the XNAS exchange. The company employs approximately 393 people. MeiraGTx Holdings plc Ordinary Shares is headquartered in NEW YORK, NY. The recorded listing date is 2018-06-08.
On this page you can find market MGTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.